GDRX241115C2500
- 0.00
- 0.000.00%
GoodRx Newsroom
GoodRx Holdings Q3 2024 Earnings Preview
GoodRx Accused of Conspiring With PBMs Over Reimbursement Fees
GoodRx to Participate in Upcoming Investor Conferences
Earnings Preview: GoodRx to Report Financial Results Pre-market on November 07
GoodRx Unveils New E-commerce Platform, Launches With Opill
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
Express News | Anyone With A Valid Prescription, Regardless Of Insurance Status, Can Use GoodRx To Purchase A 30-Day Supply Of Qsymia At The Exclusive Cash Price Of $149
GoodRx Announces Exclusive Low Cash Price for QSYMIA, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
Express News | GoodRx Announces Exclusive Low Cash Price for Qsymia®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
GoodRx Holdings Strengthens Board With New Appointment
Ronald E. Bruehlman Joins GoodRx Board of Directors
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings (GDRX) Receives a Buy From RBC Capital
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
GoodRx Partnering With Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers
The Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Don't Inspire Confidence
GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call
GoodRx Holdings Inc (GDRX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $12